Abstract
Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d’Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.
Keywords
Leishmania; Liposomal amphotericin B; Systemic therapy
Bibliographic citation
Ubals M, Bosch-Nicolau P, Sánchez-Montalvá A, Salvador F, Aparicio-Español G, Sulleiro E, et al. Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B. Pathogens. 2021 Oct;10(10):1253.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/7496This item appears in following collections
- HVH - Articles científics [2504]
The following license files are associated with this item: